ERS Genomics and genOway enter CRISPR/Cas9 agreement

Dublin, Ireland & Lyon, France, June 07, 2021 – ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and genOway, a leader in conceiving and developing genetically engineered preclinical research models, today announced a non-exclusive license agreement granting genOway past and future access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

“CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionized many research areas. At ERS, we are committed to make this technology broadly available. We are very pleased to support genOway’s development with this license agreement,” said Eric Rhodes, CEO of ERS Genomics.

“This license from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering,” said Alexandre Fraichard, CEO of genOway. “This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications.”

About ERS Genomics

ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.

genOwayについて

Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. genOway has an international team that employs passionate and dedicated people from 18 different nationalities. Its clients include 380 academic institutions and 170 life sciences companies, with 17 of the top 20 pharma. genOway strives to become the preferred partner of all scientists seeking innovative and reliable research tools.

連絡先

Sandrine Carteau – genOway – carteau@genoway.com
Katie Odgaard - Zyme Communications - katie.odgaard@zymecommunications.com